Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers
2024

Combining Anti-Angiogenic Therapy and Immune Checkpoint Inhibitors for Digestive System Cancers

publication Evidence: moderate

Author Information

Author(s): Xu Qinlan, Dong Shao

Primary Institution: The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China

Hypothesis

Can the combination of anti-angiogenic therapy and immune checkpoint inhibitors improve treatment outcomes for digestive system cancers?

Conclusion

The combination of anti-angiogenic therapy and immune checkpoint inhibitors shows promise in enhancing treatment efficacy and improving patient outcomes in digestive system cancers.

Supporting Evidence

  • The combination of anti-angiogenic therapy and immune checkpoint inhibitors can enhance anti-tumor immunity.
  • Clinical trials have shown improved patient outcomes when these therapies are used together.
  • Research indicates that normalizing tumor vasculature can improve immune cell infiltration.

Takeaway

This study looks at how two types of cancer treatments can work better together to help patients with digestive system cancers.

Methodology

This review summarizes recent advances in combining anti-angiogenic therapy and immune checkpoint inhibitors for treating digestive system cancers, focusing on clinical trials and preclinical studies.

Potential Biases

Potential biases may arise from the selective inclusion of studies and the evolving nature of cancer treatment.

Limitations

The review excludes failed and repetitive trials and is limited to anti-PD-1 and anti-PD-L1 therapies.

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1487610

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication